Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Breast Cancer, Colorectal Cancer, Non-Small-Cell Lung Cancer | Access and Reimbursement | Biomarkers in Oncology | China | 2016
Introduction Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as…
Rheumatoid Arthritis/Systemic Lupus Erthyematosus | Access and Reimbursement | US | 2016
Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic and, in many cases, debilitating diseases requiring lifelong treatment. Costs associated with biologic treatment for RA…
U.S. Clinician and Payer Receptivity to Immune Checkpoint Inhibitors in Oncology | Physician & Payer Forum | US | 2015
Ushering in a New Era of Cancer Immunotherapies in NSCLC, Malignant Melanoma, Renal Cell Carcinoma, and SCCHN The field of cancer immunotherapy has witnessed considerable advances over the past few…
Non-Small-Cell Lung Cancer (The Dynamic NSCLC Market: How Will European Payer and Physician Attitudes Shape This Highly Lucrative Market?) | Physician & Payer Forum | EU5 | 2015
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…
What Are the U.S. Market Access Levers and Hurdles Facing Orally Administered, Small-Molecule Targeted Oncology Drugs for Renal Cell Carcinoma and Hepatocellular Carcinoma? | Physician & Payer Forum | US| 2015
A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to…
Current and Emerging Small-Molecule Targeted Agents in Key Oncology Indications | Physician & Payer Forum | Brazil and Mexico | 2015
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico Small molecule therapies offer specific targeting of the aberrant cellular…
Current and Emerging Small-Molecule Targeted Agents for NSCLC | Physician & Payer Forum | US | 2015
A Survey of Oncologists and MCO Pharmacy and Medical Directors Targeted small-molecule agents have emerged as key treatment options for biomarker-defined non-small-cell lung cancer (NSCLC)…
